Baldwin Wealth Partners’s Nuvectis Pharma NVCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.62M | Sell |
350,461
-8,000
| -2% | -$59.8K | 0.18% | 74 |
|
|
2025
Q1 | $3.5M | Buy |
358,461
+2,500
| +0.7% | +$24.4K | 0.25% | 64 |
|
|
2024
Q4 | $1.93M | Buy |
355,961
+181,831
| +104% | +$984K | 0.13% | 84 |
|
|
2024
Q3 | $1.1M | Buy |
174,130
+5,500
| +3% | +$34.6K | 0.07% | 123 |
|
|
2024
Q2 | $1.07M | Buy |
168,630
+14,500
| +9% | +$91.8K | 0.08% | 100 |
|
|
2024
Q1 | $1.26M | Buy |
154,130
+12,090
| +9% | +$99.1K | 0.1% | 100 |
|
|
2023
Q4 | $1.18M | Buy |
142,040
+25,660
| +22% | +$214K | 0.09% | 99 |
|
|
2023
Q3 | $1.5M | Buy |
116,380
+26,319
| +29% | +$339K | 0.13% | 91 |
|
|
2023
Q2 | $1.44M | Sell |
90,061
-53,739
| -37% | -$858K | 0.12% | 99 |
|
|
2023
Q1 | $1.89M | Buy |
143,800
+10,500
| +8% | +$138K | 0.16% | 92 |
|
|
2022
Q4 | $1,000K | Buy |
133,300
+300
| +0.2% | +$2.25K | 0.09% | 112 |
|
|
2022
Q3 | $943K | Buy |
133,000
+12,000
| +10% | +$85.1K | 0.13% | 71 |
|
|
2022
Q2 | $1.36M | Buy |
+121,000
| New | +$1.36M | 0.18% | 61 |
|